ShengFa Su
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer (NCT03613753) | ShengFa Su | 2018-06-01 |
Track ShengFa Su automatically
Every clearance here is in the API, with alerts when new ones post.